Abstract
Background: Specific strains of Lactobacillus acidophilus are known to inhibit intestinal cell adhesion and invasion by enterovirulent bacteria. As L. acidophilus can survive transiently in the human stomach, it may downregulate Helicobacter pylori infection. Methods: The ability of L. acidophilus (johnsonii) La1 supernatant to interfere with H. pylori bacterial growth, urease activity, and adhesion to epithelial cells was tested in vitro. Its effect on H. pylori infection in volunteers was monitored in a randomized, double-blind, controlled clinical trial, using a drinkable, whey-based, La1 culture supernatant. H. pylori infected volunteers were treated 14 days with 50 ml of La1 supernatant four times a day combined with either omeprazole 20 mg four times a day or with placebo. Infection was assessed by breath test, endoscopy, and biopsy sampling, performed at inclusion, immediately at the end of the treatment (breath test only), and 4 weeks after the end of the treatment. Results: La1 supernatant inhibited H. pylori growth in vitro, regardless of previous binding of H. pylori to epithelial cells. In 20 subjects (8 females, 12 males, mean age 33.1 years) a marked decrease in breath test values was observed immediately after treatment with La1 supernatant, both in the omeprazole and in the placebo group (median 12.3 vs. 28.8 and 9.4 vs. 20.4, respectively; p < 0.03). In both treatment groups, breath test values remained low 6 weeks after treatment (omeprazole treated 19.2, placebo treated 8.3; p < 0.03 vs. pretreatment), but the persistence of H. pylori infection was confirmed in gastric biopsies. Conclusion: La1 culture supernatant shown to be effective in vitro has a partial, acid-independent long-term suppressive effect on H. pylori in humans.
Journal Section:
Original Paper: <i>Helicobacter pylori</i>
References
1.
Newman D: The treatment of cystitis by intravesical injections of lactic bacillus cultures. Lancet 1915;ii:330.
2.
Tankanow RM, Ross MB, Ertel IJ, Dickinson DG, McCormick LS, Garfinkel JF: A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990;24:382–384.
[PubMed]
3.
Gorbach SL, Chang TW, Goldin B: Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987;ii:1519.
4.
Pearce JL, Hamilton JB: Controlled trial of orally administered lactobacilli an acute infantile diarrhea. J Pediatr 1974;84:261–262.
[PubMed]
5.
Hagberg L, Bruce AW, Reid G, Svanborg Eden C, Lincoln K, Lidin-Janson G: Colonization of the urinary tract with live bacteria from the normal fecal and urethral flora in patients with recurrent symptomatic urinary tract infections; in Kass EH, Svanborg Eden C (eds): Host-Parasite Interactions in Urinary Tract Infections. Chicago, University of Chicago Press, 1989, pp 194–197.
6.
Pozo-Olano JD, Warram JH, Gomez RG, Cavazos MG: Effect of a lactobacilli preparation on traveller’s diarrhea. Gastroenterology 1978;74:829–830.
[PubMed]
7.
Mitsuoka T, Kaneuchi C: Ecology of the bifidobacteria. Am J Clin Nutr 1977;30:1799–1810.
[PubMed]
8.
Gilliland SE, Speck ML: Antagonistic action of Lactobacillus acidophilus toward intestinal and food-borne pathogens in associative culture. J Food Protect 1977;40:820–823.
9.
Hentges DJ: Inhibition of Shigella by the normal intestinal flora; in Aly R, Shinefield HR (eds): Bacterial Interference. Boca Raton, CRC Press, 1982, pp 121–132.
10.
Reid G, Bruce AW, McGroarty JA, Cheng K-J, Costerton JW: Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 1990;3:335–344.
[PubMed]
11.
Klaenhammer TR: Microbial considerations in selection and preparation of Lactobacillus strains for use as dietary adjuncts. J Dairy Sci 1982;65:1339–1349.
12.
Reid G, Bruce AW, Cook RL: Examination of strains of lactobacilli for properties that may influence bacterial interference in the urinary tract. J Urol 1987;138:330–335.
[PubMed]
13.
Kleeman EG, Klaenhammer TR: Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci 1982;65:2063–2069.
[PubMed]
14.
Conway PL, Gorbach SL, Goldin BR: Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci 1987;70:1–12.
[PubMed]
15.
Silva M, Jacobus NV, Deneke C, Gorbach SL: Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31:1231–1233.
[PubMed]
16.
Marteau P, Mikenus M, Havenaar R, Huis in’t Veld JH: Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: Validation and the effects of bile. J Dairy Sci 1997;80:1031–1037.
[PubMed]
17.
Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma (see comments). N Engl J Med 1991;325:1127–1131.
[PubMed]
18.
Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F: Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991;302:1302–1305.
[PubMed]
19.
Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267–1271.
[PubMed]
20.
Khulusi S, Mendall MA, Patel P, Levy J, Badve S, Northfield TC: Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. Gut 1995;37:319–324.
[PubMed]
21.
Stolte M, Stadelmann O, Bethke B, Burkard G: Relationships between the degree of Helicobacter pylori colonization and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995;33:89–93.
[PubMed]
22.
Atherton JC, Tham KT, Peek RM Jr, Cover TL, Blaser MJ: Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology. J Infect Dis 1996;174:552–556.
[PubMed]
23.
Goldin BR, Gorbach SL: The effect of milk and lactobacillus feeding on human intestinal bacterial enzyme activity. Am J Clin Nutr 1984;39:756–761.
[PubMed]
24.
Bernet MF, Brassart D, Neeser JR, Servin AL: Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35:483–489.
[PubMed]
25.
Michetti P, Corthésy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M, Bille J, Krähenbühl JP, Saraga E, Blum AL: Immunization of BALB/c mice against Helicobacter felis infection with H. pylori urease. Gastroenterology 1994;107:1002–1011.
[PubMed]
26.
Moshkowitz M, Peled Y, Baratz M, Halpern Z, Tiomny E, Gilat T: 14C-urea breath test – a simple, noninvasive method for the detection of Helicobacter pylori. Isr J Med Sci 1993;29:94–97.
[PubMed]
27.
Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP: Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 1989;27:2328–2330.
[PubMed]
28.
Martini MC, Lerebours EC, Lin WJ, Harlander SK, Berrada NM, Antoine JM, Savaiano DA: Strains and species of lactic acid bacteria in fermented milks (yogurts): Effect on in vivo lactose digestion. Am J Clin Nutr 1991;54:1041–1046.
[PubMed]
29.
Gilliland SE, Walker DK: Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci 1990;73:905–911.
[PubMed]
30.
Barefoot SF, Nettles CG: Antibiosis revisited: Bacteriocins produced by dairy starter cultures. J Dairy Sci 1993;76:2366–2379.
[PubMed]
31.
Barefoot SF, Klaenhammer TR: Detection and activity of lactacin B, a bacteriocin produced by Lactobacillus acidophilus. Appl Environ Microbiol 1983;45:1808–1815.
[PubMed]
32.
Jack RW, Tagg JR, Ray B: Bacteriocins of gram-positive bacteria. Microbiol Rev 1995;59:171–200.
[PubMed]
33.
Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML: In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acid and lactic acid bacteria. J Appl Bacteriol 1995;79:475–479.
[PubMed]
34.
Debongnie JC, Pauwels S, Raat A, de Meeus Y, Haot J, Mainguet P: Quantification of Helicobacter pylori infection in gastritis and ulcer disease using a simple and rapid carbon-14-urea breath test. J Nucl Med 1991;32:1192–1198.
[PubMed]
35.
Perri F, Clemente R, Pastore M, Quitadamo M, Festa V, Bisceglia M, Li Bergoli M, Lauriola G, Leandro G, Ghoos Y, Rutgeerts P, Andriulli A: The 13C-urea breath test as a predictor of intragastric bacterial load and severity of Helicobacter pylori gastritis. Scand J Clin Lab Invest 1998;58:19–27.
[PubMed]
36.
Krishnamurthy P, Parlow M, Vakil N, Phadnis SH, Dunn BE: H. pylori urease can be exclusively cytoplasmic in vivo (abstract). Gastroenterology 1998;114:189.
37.
Bazzoli F, Zagari M, Fossi S, Pozzato P, Ricciardiello L, Mwangemi C, Roda A, Roda E: Urea breath tests for the detection of Helicobacter pylori infection. Helicobacter 1997;2(suppl 1):34–37.
38.
Stermer E, Tabak M, Potasman I, Levy N, Tamir A, Neeman I: Effect of ranitidine on the urea breath test: A controlled trial. J Clin Gastroenterol 1997;25:323–327.
[PubMed]
39.
Gismondo MR, Lo Bue AM, Chisari G, Pecorella G, Malandrino G, Petralino E: Competitive activity of a bacterial preparation on colonization and pathogenicity of C. pylori: A clinical study. Clin Ter 1990;134:41–46.
[PubMed]
40.
Bazzoli F, Zagari RM, Fossi S, Morelli MC, Pozatto P, Novelli V, Ventrucci M, Mazella G, Festi D, Roda E: In vivo Helicobacter pylori clearance failure with Lactobacillus acidophilus (abstract). Gastroenterology 1992;102:38.
41.
Pedrosa MC, Golner BB, Goldin BR, Barakat S, Dallal GE, Russell RM: Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects. Am J Clin Nutr 1995;61:353–359.
[PubMed]
42.
Link-Amster H, Rochat F, Saudan KY, Aeschlimann JM: Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994;10:55–63.
[PubMed]
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1999
You do not currently have access to this content.
